Up to 70% of Orthopedic Medtech Company to Be Sold

Target deal: sale of up to 70% of the capital, maintaining a minimum 30% stake and direct operational role in management and international development.

Who we are

Italian manufacturer of orthopedic hip and knee prostheses (original and revision), including hypoallergenic solutions. Active contract manufacturing, existing customer base, and expanding distribution network.

Key Points

Industrial production with certified processes and rigorous quality standards.

Market-validated product portfolio; commercial pipeline in the EU and international markets (LATAM, MENA, etc.).

Growth levers: expansion of distributor network, clinical marketing, registrations/regulatory efforts, increased production capacity, and working capital.

Certifications & Regulatory Compliance

CE Class III (implantable prostheses), with official confirmation from the Italian National Institute of Health
MDR Transition Agreement pursuant to EU Regulation 2017/745, with 2025 update: ensures operational continuity and enhances both current inventory and future prospects.

International Commercial Portfolio

International contracts reviewed and evaluated for a three-year portfolio (2025–2027) worth €21,750,000.

They highlight international scalability and increased foreign goodwill.

What We Seek

Investor with or without experience in medical/healthcare devices or industrial sectors.

Support for commercial scaling, operations, and governance.

Flexible structure: qualified minority or majority; medium- to long-term commitment.

Management

Current team confirmed at the helm for continuity and transfer of expertise; plan acceleration.

Earn-out/MIP availability based on shared KPIs.

Financial Data & Due Diligence

Detailed financial information available upon NDA.

Vendor Due Diligence available for fast and transparent processes.

Indicative Valuation

Based on balance sheet data, foreign business portfolio, and active CE certifications, estimated net economic value: €8,400,000.

Term Sheet (indications)

Valuation and structure to be agreed upon based on share and terms; possible combination of equity and vendor financing.

Timeframe compatible with orderly closing and assisted transition.

Call to Action

Available for an exploratory meeting (virtual or on-site) and sharing of IM light and NDA for access to the data room.